• 1
    Bradding P, Feather IH, Wilson S, Holgate ST, Howarth PH. Cytokine immunoreactivity in seasonal rhinitis: regulation by a topical corticosteroid. Am J Respir Crit Care Med 1995;151:19006.
  • 2
    Sim TC, Reece LM, Hilsmeier KA, Grant JA, Alam R. Secretion of chemokines and other cytokines in allergeninduced nasal responses: inhibition by topical steroid treatment. Am J Respir Crit Care Med 1995;152:92733.
  • 3
    Meltzer EO. Nasal cytological changes following pharmacological intervention. Allergy 1995;50 Suppl 23:1520.
  • 4
    Godthelp T, Holm AF, Blom H, Klein-Jan A, Rijntjes E, Fokkens WJ. The effect of fluticasone propionate aqueous nasal spray on nasal mucosal inflammation in perennial allergic rhinitis. Allergy 1995;50 Suppl 23:214.
  • 5
    Wang DY, Clement P, Smitz J, De Waele M, Derde M-P. Correlations between complaints. inflammatory cells and mediators after nasal allergen challenge and during natural allergen exposure. Int Arch Allergy Immunol 1995;106:27885.
  • 6
    Wang DY, Clement P, Smitz J. Effect of H1 and H2 antagonists on nasal symptoms and mediator release in atopic patients after nasal allergen challenge during the pollen season. Acta Otolaryngol (Stockh) 1996;116:916.
  • 7
    Wang D, Smitz J, De Waele M, Clement P. Effect of topical applications of budesonide and azelastine on nasal symptoms, eosinophil count and mediator release in atopic patients after nasal allergen challenge during the pollen season. Int Arch Allergy Immunol 1997;114:18592.
  • 8
    Wang D, Smitz J, Waterschoot S, Clement P. An approach to the understanding of the nasal early-phase reaction induced by nasal allergen challenge. Allergy 1997;52:1627.
  • 9
    Biewenga J, Stoop AE, Baker HE, et al. Nasal secretions from patients with polyps and healthy individuals, collected with a new aspiration system: evaluation of total protein and immunoglobulin concentrations. Ann Clin Biochem 1991;28:2606.
  • 10
    Wang DY, Clement P, Smitz J, Derde M-P. Concentrations of chemical mediators in the nasal secretions after nasal allergen challenge in atopic patients. Eur Arch Otorhinolaryngol 1995;252 Suppl:S403.
  • 11
    Clement PAR, van Dishoeck A, van de Wal J, Stoop P, Hoek T, van Strick R. Nasal provocation and passive anterior rhinomanometry (PAR). Clin Allergy 1981;11:293301.
  • 12
    Gerth van, Wijk R, Dieges PH. Comparison of nasal responsiveness to histamine, methacholine and phentolamine in allergic rhinitis patients and controls. Clin Allergy 1987;17:56370.
  • 13
    Knani J, Campbell A, Enander I, Peterson CGB, Michel FB, Bousquet J. Indirect evidence of nasal inflammation assessed by titration of inflammatory mediators and enumeration of cells in nasal secretions of patients with chronic rhinitis. J Allergy Clin Immunol 1992;90:8819.
  • 14
    Hills M, Armitage P. The two-period crossover trial. Br J Clin Pharmacol 1979;8:720.
  • 15
    Howarth PH. The cellular basis for allergic rhinitis. Allergy 1995;50 Suppl 23:610.
  • 16
    Rogenes P, van As A, Krai K. Fluticasone propionate 200 μg once a day relieves symptoms of allergic rhinitis within 24 to 48 hours. Allergy Clin Immunol News 1991;Suppl 1 (Abstract 942).
  • 17
    Meltzer EO. An overview of current pharmacotherapy in perennial rhinitis. J Allergy Clin Immunol 1995;95:1097110.
  • 18
    Berman BA. Allergic rhinitis: mechanisms and management. J Allergy Clin Immunol 1988;81:98091.
  • 19
    Goulding NJ, Guyre PM. Regulation of inflammation by lipocortin 1. Immunol Today 1992;13:2957.
  • 20
    Norman PS. Allergic rhinitis. J Allergy Clin Immunol 1985;75:53145.
  • 21
    Juliusson S, Holmberg K, Karlsson G, Enerbäck L, Pipkorn U. Mast cells and mediators in the nasal mucosa after allergen challenge. Effects of four weeks' treatment with topical glucocorticoid. Clin Exp Allergy 1993;23:5919.
  • 22
    Lozewicz S, Wang J, Duddle J, et al. Topical glucocorticoids inhibit activation by allergen in the upper respiratory tract. J Allergy Clin Immunol 1992;89:9517.